four-rules-for-healthcare-ai-after-go-live

Four Rules for Healthcare AI After Go-Live

AI Revolutionized Healthcare 5 min read

The AI Contract Is Signed. Now Who Owns the Outcome?

Four Rules for Healthcare AI After Go-Live

Healthcare organizations can spend months selecting an AI tool and still leave the most important question unanswered: what has to happen after go-live for this thing to change the way the organization actually operates?

The demo looked good. Security signed off. The contract is done. Training is on the calendar. Then the tool meets a real Tuesday morning. A physician is behind. A nurse has three other priorities. IT has a queue. An operations leader is trying to keep the day moving.

That is the part of AI implementation that gets less attention. The technology may work. The organization still has to make it usable. Research on digital health and AI implementation keeps pointing back to the same basic issue: workflow, leadership, infrastructure, training, stakeholder engagement, and local context affect whether technology is actually used. The practical question is what a healthcare organization does with that after the purchase.

four-rules-for-healthcare-ai-after-go-live

Turn the sales promise into an operating promise

“Save time,” “improve decisions,” and “reduce administrative burden” are reasons to buy something. They are not implementation plans.

Before rollout, take the reason the organization bought the AI and make it specific enough to observe. What is supposed to change in the work? Who should feel the difference? What would count as evidence that the promise actually showed up?

Documentation Time

Measure the net time saved after review and manual correction steps are fully included.

Faster Decisions

Identify exactly which decision should move faster and explicitly name who owns it.

Fewer Handoffs

Name the specific manual handoff process that should disappear entirely post go-live.

This sounds basic, but it is where a lot of implementations get slippery. A tool can be technically live while the original business case stays vague enough that nobody can tell whether it worked. The vendor can show that the product functions. The healthcare organization still has to define what better work looks like on its side.

If nobody can say what should be different after go-live, the team has a deployment date. It does not yet have an operating outcome.
Rule 02

Give the handoff to somebody who can actually move decisions

Healthcare AI usually crosses more functions than the person who bought it.

Cross-Functional Complexity
Executive sponsor: Approves budget
IT: Handles integration
Security & Compliance: Set conditions
Clinicians: Use the tool
Operations: Feels workflow impact
Vendor: Training & support
That is a lot of people, and “everybody owns it” usually means nobody owns the next problem.

Name one implementation owner on the healthcare side and make the decision path clear. That person does not need to control every department, but they need access to the people who do. They also need a way to escalate issues that cannot be solved at the project level.

Clinical buy-in belongs here too. It should not be a presentation after the important decisions are finished. Put real users in front of the proposed workflow early enough that their objections can still change something.

Ask practical questions:
  • • Where would you skip this step on a busy day?
  • • What would make you distrust the output?
  • • What will create duplicate work?
  • • Who gets stuck if this part of the process is late?
A polished demo cannot answer those questions. The people doing the work can.

Use friction to test whether the handoff was real

After go-live, recurring friction is one of the fastest ways to see whether the implementation handoff actually worked.

Forms of Operational Friction
Corrections Overrides Duplicate Entry Ignored Alerts Extra Clicks Recurring Support Questions Workarounds

Corrections, overrides, duplicate entry, ignored alerts, extra clicks, recurring support questions, and workarounds are not all the same problem. Some point to the product. Some point to the workflow. Some point to training, staffing, policy, integration, or a decision nobody has the authority to make.

The mistake is treating all of that as “user resistance” and moving on.
By the second or third time the same issue appears, somebody should be able to answer three things:
1
What kind of problem is this?
2
Who owns the next decision?
3
What would make us change the workflow, retrain users, push the vendor, narrow the use case, or stop the process until the issue is fixed?

That matters even more in healthcare because the answer cannot be “the AI said so.” Human review, escalation, and professional judgment have to be built into the operating path, not added after something goes wrong.

Friction is not automatically evidence that the technology failed. It is evidence that somebody needs to find out whether the problem is the technology, the workflow, or the fact that nobody owns the decision between them.

Reopen the business case after 30, 60, and 90 days

Go-live is a date. It is not proof that the investment worked.

The first few months should test the original reason the organization bought the technology. Keep the scorecard small enough that somebody will actually use it.

Adoption

Are the intended users actually using it?

Workflow

Is the work faster, simpler, or more reliable after the new steps are included?

Reliability

How often are users correcting, overriding, bypassing, or escalating the output?

Value

Is the clinical, operational, financial, or staff outcome that justified the purchase moving in the right direction?

Those measures have to be read together. High use can hide a bad workflow if people are required to use the tool. Positive feedback can hide reliability problems. Good technical performance can mean very little if the output arrives too late to matter.

The review should force a decision:
Keep it Fix it Narrow it Expand it Or stop
That last option matters. A signed contract can create pressure to defend the purchase. It should not create a permanent obligation to defend a weak implementation.
The organizations that get real value from these tools will be:
  • Specific about the workflow
  • Clear about ownership
  • Willing to learn from friction
  • Disciplined enough to check the business case post go-live

That is not the flashy part of AI. It is the part that decides whether the technology becomes useful work or another expensive system sitting beside the real work.

References

  • Hassan, M., Kushniruk, A., & Borycki, E. (2024). Barriers to and facilitators of artificial intelligence adoption in health care: Scoping review. JMIR Human Factors, 11, e48633.
  • Preti, L. M., Ardito, V., Compagni, A., Petracca, F., & Cappellaro, G. (2024). Implementation of machine learning applications in health care organizations: Systematic review of empirical studies. Journal of Medical Internet Research, 26, e55897.

Top 5 AI Tools for Oncologists

AI in Oncology Top 5 AI Tools for Medical Oncologists: What Clinicians Need to Know Discover how…

AI in Drug Discovery

Home AI in Healthcare AI in Drug Discovery 🧬 AI Revolutionized Healthcare Artificial Intelligence in…

AI-Powered Adaptive BMR Calculator

🤖 AI-Driven Clinical Nutrition AI-Powered Adaptive BMR & Metabolic Adaptation Calculator…
Steve DeWitt

Steve DeWitt works across healthcare commercialization, strategic accounts, implementation, and organizational execution. His writing focuses on what happens after technology is purchased: adoption, ownership, workflow, and whether expected value actually shows up in day-to-day work.

View All Post

Leave a Reply

Your email address will not be published. Required fields are marked *